• Dermapharm confirmed FY 2026 guidance for revenue of €1.18 billion-€1.22 billion, versus €1.17 billion in the previous year.
• Adjusted EBITDA forecast maintained at €331 million-€341 million, versus €324.8 million a year earlier.
• Outlook supported by H1 revenue of €591 million, up 2.9%, adjusted EBITDA of €163.2 million, up 10.3%.
• H1 earnings after tax rose 26.2% to €68.3 million; operating cash flow increased €35.2 million to €105.3 million.
• Net debt to adjusted EBITDA stood at 3.0x at June 30; equity ratio fell to 23.8% following a €181.1 million share buyback.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermapharm Holding SE published the original content used to generate this news brief on August 25, 2026, and is solely responsible for the information contained therein.